Valneva surges after EU regulator validates Lyme disease vaccine application
14/08/2026 08:36
BUZZ-Valneva surges after EU regulator validates Lyme disease vaccine application ** French vaccine maker Valneva VLS.PA jumps 15.6% after the European Medicines Agency validated the marketing application for its Lyme disease vaccine candidate, developed with partner Pfizer PFE.N
** The validation marks a key regulatory milestone for the Lyme programme, which Kempen analysts describe as "the key" driver of the investment case
** The broker had flagged a potential filing by Pfizer during H2 2026 as a critical near-term catalyst, with a possible U.S. approval decision expected in H2 2027
** Kempen notes that Pfizer's latest commentary "continues to signal optimism on the vaccine candidate's prospects of approval"
** The shares are on track for their best day since August 2025 if the gains hold
(Reporting by Jerome Terroy)
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency